Vanguards of Healthcare by Bloomberg Intelligence

IRhythm Pushes a Proactive Approach to Monitoring

Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA

RTW’s Rod Wong on Biotech’s Revival and the Global Shift

Cortica’s Plan to Bring Value-Based Care to Autism

Xontogeny's Case for Drug Developers Over Storytellers

Roivant’s Playbook for Finding Value Others Miss in Biotech

Virta Health’s Push to Reverse Metabolic Disease at Scale

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough

Abridge Moving AI From Scribing to Clinical Workflows

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing

Xaira’s War on Trial-and-Error Drug Development

The integration of artificial intelligence into the drug discovery process aims to reduce development timelines and improve success rates by shifting from artisanal, trial-and-error methods to data-driven, in silico modeling. Xaira, led by CEO Marc Tessier-Lavigne, focuses on three critical stages: target identificatio...

AVS’ Toland on Next Lithotripsy Launch

Halle Tecco on AI, Boom-Bust Cycles and Building Better Care

Highridge Goes Private to Expand Differentiated Offering in Spine

Dexcom Aims to Expand CGM Benefits to All Diabetic Patients and Beyond

AliveCor’s Abani Uses Amazon Experience to Democratize ECG Tech

John Maraganore Reflects on the Long Game of RNAi and Drug Innovation

Carlsmed Personalizes Spine with AI

Precision Cardiology With Cytokinetics